



**SYNCOM**  
Healthcare Limited

Date: 14.09.2017

To,  
The Corporate Relationship Department,  
Bombay Stock Exchange Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Mumbai – 400 001  
Company Code: 533157

To,  
The Secretary,  
National Stock Exchange of India Limited,  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai 400051  
Company ISIN: INE602K01014

**Sub:- Revised Financial Results and Limited Review for the quarter ended on 30<sup>th</sup> June 2017**

Dear Sir,

Please find enclosed the Revised Financial Results and Limited Review for the quarter ended on 30th June 2017

Kindly take the same on your record.

Thanking you,

**For Syncom Healthcare Limited**

**Charu Srivastava**  
Company Secretary  
M.No.- A27108



Encl:-A/a



CIN : L51397MH2002 PLC136652



Regd. Office : 502 Advent Atria, Chincholi Bunder, Malad (W)  
Mumbai - 400064 INDIA. Tel : +91 (022) 2881 3796 / 97

Works : D - 42 IIE Sidcul Selaqui, Dehradun - 248197 Uttarakhand, INDIA  
Tel : +91 (135) 2699131 Fax : +91 (135) 2698220. Website : www.syncom.in



# S. G. KABRA & CO.

## CHARTERED ACCOUNTANTS

Wavell House, 1st Floor, 1st Dhobi Talao Lane, Mumbai - 400 002.

Tel.: 2201 0708 / 2200 4533 • Fax : 2200 1497 • E-mail : info@sgkabra.com • Website : www.sgkabra.com

### Limited Review Report

To,  
Board of Directors,  
Syncom Healthcare Limited

1. We have reviewed the accompanying statement of unaudited financial results of **Syncom Healthcare Limited** (the Company') for the quarter ended June30, 2017 which has been initialed by us for identification purpose except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosure made by the management and have not been verified by us. This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.

This statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.

2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the applicable Accounting Standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI ( Listing Obligation and Disclosure Requirement) Regulation, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.



4. The comparative financial information of the Company for the quarter ended 30 June, 2016 prepared in accordance with IndAS.

For S.G.Kabra & Co.  
Chartered Accountants  
FRN: 104507W



Malvika Mitra  
Partner

M.No.044105

Place: Mumbai

Date: 10/07/2017



**SYNCOM**  
Healthcare Limited  
(An ISO 9001 : 2000 Certified Company)

**SYNCOM HEALTHCARE LIMITED**  
**CIN: L51397MH2002PLC136652**

Regd. Off. : 502, Advent Atria, Chincholi Bunder Road, Opp Kingston Complex, Malad (West), Mumbai- 400 064

**STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULT FOR QUARTER ENDED JUNE 30, 2017**

(Amount in Lakh )

Sr. No	Particulars	Quarter ended	
		Quarter ended 30-06-2017 (Unaudited)	Quarter ended 30-06-2016 (Unaudited)
1	<b>Income</b>		
a	Revenue from operations	516.66	1,678.10
b	Other income	-	26.20
	<b>Total income</b>	<b>516.66</b>	<b>1,704.30</b>
2	<b>Expenses</b>		
a	Cost of materials consumed	283.00	978.33
b	Purchases of stock-in-trade	-	48.09
c	Changes in inventories of finished goods, work-in-progress and stock-in-trade	20.81	72.00
d	Employee benefit expense	222.84	231.58
e	Finance costs	1.13	73.06
f	Depreciation, depletion and amortisation expense	93.58	110.09
g	Other Expenses	285.51	263.94
	<b>Total expenses</b>	<b>906.88</b>	<b>1,777.10</b>
3	<b>Total profit before exceptional items and tax</b>	<b>(390.22)</b>	<b>(72.80)</b>
4	<b>Exceptional items</b>	<b>4,386.50</b>	<b>-</b>
5	<b>Total profit before tax</b>	<b>(4,776.72)</b>	<b>(72.80)</b>
6	<b>Tax expense</b>		
a	Current tax	-	-
b	Deferred tax	-	17.65
	<b>Total tax expenses</b>	<b>-</b>	<b>17.65</b>
7	<b>Total profit (loss) for period</b>	<b>(4,776.72)</b>	<b>(90.45)</b>
8	<b>Other comprehensive income net of taxes</b>	<b>-</b>	<b>-</b>
(A)(i)	Items that will not be reclassified to Profit & Loss	1.84	1.84
(A)(ii)	Income Tax relating to items that will not be reclassified to Profit & Loss	-	-
(B)(i)	Items that will be reclassified to Profit & Loss	-	-
(B)(ii)	Income Tax relating to items that will be reclassified to Profit & Loss	-	-
	<b>Total other comprehensive income net of taxes</b>	<b>-</b>	<b>-</b>
9	<b>Total Comprehensive Income (loss) for the period</b>	<b>(4,778.56)</b>	<b>(92.29)</b>
10	<b>Details of equity share capital</b>		
a	Paid-up equity share capital	4000.00	4000.00
b	Face value of equity share capital	10.00	10.00
11	<b>Earnings per share</b>		
i	Basic earnings (loss) per share from continuing operations	(11.95)	(0.23)
ii	Diluted earnings (loss) per share from continuing operations	(11.95)	(0.23)



*[Signature]*



CIN : L51397MH2002PLC136652

**Works :** D-42, UPSIDC Industrial Area, Selaqui, Dehradun 248 197 (Uttarakhand)  
**Tel. :** 0135-2699131, +91 7060088770, +91 7060008770, **email :** works@syncom.in  
**Regd. Off. :** 502, Advent Atria, Chincholi Bunder, Malad (W) MUMBAI - 400064. INDIA  
**Tel. :** 022-28813796, +91 70457 99503, **Website :** http://www.syncomhealthcare.com



**NOTE**

- The results for the Quarter ended June 30, 2017 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on 10.07.2017. The above results for the quarter ended June 30, 2017 have been reviewed by Statutory Auditors of the Company in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015. The IND AS compliant financial results pertaining to the relevant previous period have not been subject to the Limited Review. However, the Company's Management has exercised necessary due diligence to ensure that the financial results for the comparative period provide a true and fair view of its affairs.
- The statement has been prepared in accordance with the Companies ( Indian Accounting Standard ) Rules, 2015 (Ind AS) prescribed under section 133 of Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Beginning April 1, 2017, the Company has for the first time adopted Ind AS with a transition date of April 1, 2016.
- As per the requirements of Ind AS-108, no disclosure is required as the Company is operating in single business segment i.e. "Pharmaceutical Formulations"
- The statement does not include IND AS compliant results for preceding quarter and previous year ended March 31, 2017, as it is not mandatory as per SEBI's circular dated July 5, 2016.
- Previous quarter figures have been regrouped / rearranged wherever considered necessary.
- The unaudited Standalone financial results of the Company for the quarter ended 30th June, 2017 are available on the Company's website i.e www.syncomhealthcare.com and also available on BSE website ie. www. bseindia.com
- The reconciliation of net profit/loss for the quarter ended 30th June, 2016 in accordance with Indian GAAP to total comprehensive income in accordance with Ind AS is given below:

Description	Amount (Rs. In Lakh) for quarter ended June
Net Profit/ (Loss) after tax as per previous GAAP	(120.46)
Net effective interest expense on borrowing and others	(0.51)
Amortization charge on finance lease	(0.13)
Changes in actuarial assumption transferred through OCI	1.84
Other adjustments	28.80
Net Profit after tax before OCI as per Ind AS	(90.45)
Other Comprehensive income (Net of tax Impact)	(1.84)
Total Comprehensive income after tax as per Ind AS	(92.29)

By order of the Board

Ajay Shankarlal Bankda  
Managing Director  
DIN: 0013796

Place : Mumbai  
Date: 10.07.2017



CIN : L51397MH2002PLC136652

Works : D-42, UPSIDC Industrial Area, Selaqui, Dehradun 248 197 (Uttarakhand)  
Tel. : 0135-2699131, +91 7060088770, +91 7060008770, email : works@syncom.in  
Regd. Off. : 502, Advent Atria, Chincholi Bunder, Malad (W) MUMBAI - 400064. INDIA  
Tel. : 022-28813796, +91 70457 99503, Website : http://www.syncomhealthcare.com